Dividend Informer Q1 2025 Update: AbbVie
The quarter was volatile in the wake of the Q4 earnings report, but showed revenue growth led by immunology and neuroscience segments.
⚠️This news update is exclusive to paid Dividend Informer subscribers. Here is our team’s update on a covered stock. See below for updated buy/sell prices, a report on recent conditions and expectati…